Table 2.
Association of clinical features and FOXC1 protein level in 43 LSCC patients.
| Variables | No. (n=43) |
FOXC1 protein level (n, %) | P | FOXC1 protein level | P ** | |
|---|---|---|---|---|---|---|
| Low | High | Mean rank | ||||
| Age, years (range 45-76) | ||||||
| ≤59 | 19 | 5 (26.3) | 14 (73.7) | 0.294 | 23.84 | 0.300 |
| >59 | 24 | 10 (41.7) | 14 (58.3) | 20.54 | ||
| Gender | ||||||
| Male | 39 | 15 (38.5) | 24 (61.5) | 0.280* | 21.23 | 0.129 |
| Female | 4 | 0 (0.0) | 4 (100.0) | 29.50 | ||
| Differentiation | ||||||
| Well | 18 | 6 (33.3) | 12 (66.7) | 0.856 | 22.33 | 0.858 |
| Moderate or poor | 25 | 9 (36.0) | 16 (64.0) | 21.76 | ||
| Tumor stage | ||||||
| T1+T2 | 25 | 10 (40.0) | 15 (60.0) | 0.407 | 20.90 | 0.412 |
| T3+T4 | 18 | 5 (27.8) | 13 (72.2) | 23.53 | ||
| Cervical lymph node | ||||||
| N0 | 24 | 12 (50.0) | 12 (50.0) | 0.019 | 18.75 | 0.021 |
| N+ | 19 | 3(15.8) | 16 (84.2) | 26.11 | ||
| Clinical stage | ||||||
| I + II | 14 | 9 (64.3) | 5 (35.7) | 0.005 | 15.68 | 0.005 |
| III + IV | 29 | 6 (20.7) | 23 (79.3) | 25.05 | ||
| Tumor site | ||||||
| Supraglottis or subglottis | 16 | 4 (25.0) | 12 (75.0) | 0.295 | 24.13 | 0.301 |
| Glottis | 27 | 11 (40.7) | 16 (59.3) | 20.74 | ||
| miR-204-5p level | ||||||
| Low | 21 | 4 (19.0%) | 17 (81.0%) | 0.033 | 25.40 | 0.035 |
| High | 22 | 11 (50.0%) | 11 (50.0%) | 18.75 | ||
| FOXC1 mRNA level | ||||||
| Low | 21 | 11 (52.4%) | 10 (47.6%) | 0.019 | 18.24 | 0.020 |
| High | 22 | 4 (18.2%) | 18 (81.8%) | 25.59 | ||
* By Fisher's exact test, ** by Mann-Whitney U test.